shutterstock_40412344_-orla

Orla / Shutterstock.com

30 September 2019Big PharmaRory O'Neill

Genetic research: DNA payday

After decades of reliance on blockbuster drugs, pharmaceutical companies are increasingly having to face up to the challenge of diversifying their businesses.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

UKIPO rejects Boehringer’s SPC for horse inhaler

Bayer, Orion take on Indian generic over $117bn drug

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?

BMS faces fresh lawsuit over alleged cancer drug monopoly

WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations

Boies Schiller Flexner adds three-strong litigation team